News | September 09, 2011

Angioslide Announces European Launch of New 300 mm SFA Treatment Device

September 9, 2011 — Angioslide Ltd. announced the first procedures with its new 5 x 300 mm Proteus device for treating the superficial femoral artery (SFA). The technology combines a percutaneous transluminal angioplasty (PTA) balloon and embolic capture of particles in one device. The new 5 x 300 mm size joins Angioslide's current dedicated product line solutions for the lower limbs.

Initial treatments using the new device were conducted in leading world centers, Parkkrankenhaus Leipzig and Herzzentrum Bad Krozingen, located in Germany. The technology makes it possible to treat lesions up to 300 mm with one device, while providing an immediate solution for embolic capture.

"Angioslide's breakthrough technology, now available also in 300 mm length as well, is a unique solution for lesions with high level of embolic material, including chronic total occlusions (CTO), in stent-restenosis, thrombus containing lesions and post atherectomy PTA," said Prof. Thomas Zeller, head of the angiology department, Heart Center Bad-Krozingen.

Prof. Dierk Scheinert, head of the department of angiology, Park-Krankenhaus Leipzig, adds, "We have been using the Proteus product line as part of our daily practice for a few years, and are working closely with the Angioslide team. I welcome the release of the 5 x 300 mm. We can now use one device to treat patients with SFA diseases, which facilitates the procedural flow and makes the intervention cost-effective."

There is a growing need for expanding the current interventional “tool box” to accommodate procedures designed specifically to treat long and diffuse lesions in a quick and effective manner. This need stems from the increase in life expectancy, diabetes prevalence, and number of high-risk patients, together with the shift toward an "endovascular-first" approach as a preferred procedure over surgical revascularization.

The Proteus 5X300 mm is currently released for the European market only. It is undergoing an evaluation regulatory process with the U.S. Food and Drug Administration (FDA).

For more information: www.angioslide.com

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init